Evidence map›Paper›PMID 33435371›Full record

ArticleInternational journal of molecular sciences2021

Artesunate Switches Monocytes to an Inflammatory Phenotype with the Ability to Kill Leukemic Cells.

Rubia Isler Mancuso, Sara Teresinha Olalla Saad, Juliana Hofstätter Azambuja

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Recent advances in non-invasiveBiomaterials science · 2025
    Review
  2. Article
  3. Article
  4. Anti-tumor mechanism of artesunate.Frontiers in pharmacology · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rubia Isler MancusoHematology and Transfusion Medicine Center, University of Campinas, Campinas 13083-970, Brazil.ORCID 0000-0001-6725-3131
Sara Teresinha Olalla SaadHematology and Transfusion Medicine Center, University of Campinas, Campinas 13083-970, Brazil.ORCID 0000-0003-0809-8068
Juliana Hofstätter AzambujaHematology and Transfusion Medicine Center, University of Campinas, Campinas 13083-970, Brazil.ORCID 0000-0002-2416-7724
Universidade Estadual de Campinas (UNICAMP) · BR

Funding

.and Ministry of Science, Technology, Innovations and Communications (CNPq) 142286/2017.and Ministry of Science, Technology, Innovations and Communications (CNPq) 301676/2013-5São Paulo Research Foundation (FAPESP). 2017/21801-2
6 · The paper itself

Abstract

Monocytes are components of the tumor microenvironment related to cancer progression and immune escape. Therapeutic strategies for reprogramming monocytes from a tumor-supporting phenotype towards a tumoricidal phenotype are of great interest. Artesunate (ART) may be an interesting option for cancer treatment; however, the role of ART in regulating the inflammatory tumor microenvironment has not yet been investigated. Our aim is to evaluate the immunomodulatory potential of ART in vitro in human primary monocytes. ART treatment induced an increase in inflammatory monocytes (CD14

Indexed as

Antineoplastic AgentsApoptosisArtesunateCell Line, TumorCells, CulturedChemokine CCL2HumansImmunologic FactorsImmunotherapyInterleukin-1betaLeukemiaMonocytesTumor EscapeAntineoplastic AgentsArtesunateCCL2 protein, humanChemokine CCL2Immunologic FactorsInterleukin-1betaartesunatehematologic malignanciesimmunotherapymonocytes

Identifiers

PMID33435371
PMCPMC7827848
OpenAlexW3120670308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.